Organisation paid for research Program year 2025 Source: CMS Open Payments

Cardiovascular Consultants PC

Neither a doctor nor a teaching hospital

Research payments

$634,364

276 payments

Through program year 2025, Cardiovascular Consultants PC is reported as receiving $634,364 in research payments, across 276 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $475,686 260
2024 Research $128,515 6
2023 Research $28,205 3
2022 Research $303 1
2020 Research $1,656 6

Breakdown

Who paid Research payments · program years 2020–2025
  1. Boehringer Ingelheim International GmbH $482,669 249 payments
  2. Boehringer Ingelheim Pharma GmbH & Co.KG $145,953 19 payments
  3. Esperion Therapeutics, Inc. $5,438 7 payments
  4. Medtronic, Inc. $303 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $211,608 132 payments
  2. BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) $103,215 3 payments
  3. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $98,694 63 payments
  4. EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% $96,104 53 payments
  5. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $69,280 12 payments
  6. Empagliflozin for prevention of HHF and death afte $24,422 2 payments
  7. BI 456906 in NASH F4 - pivotal trial $9,000 1 payment
  8. BI 456906 in NASH F2/F3 - pivotal trial $9,000 1 payment
  9. Empagliflozin for prevention of HHF and death after an AMI $7,300 1 payment
  10. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $5,438 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record